|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:none
|
|
gptkbp:ceo
|
Maria Fardis
|
|
gptkbp:clinical_trial
|
Phase 2
Phase 3
TIL therapy
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:focus
|
gptkb:Cell
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
M. Celeste Simon
|
|
gptkbp:headcount
|
200+
|
|
gptkbp:headquarters
|
gptkb:San_Carlos,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Iovance Biotherapeutics
|
|
gptkbp:investment
|
institutional investors
various venture capital firms
|
|
gptkbp:key_people
|
gptkb:David_Chang
gptkb:Michael_A._Heller
gptkb:David_M._Hyman
gptkb:David_A._Hyman
gptkb:John_R._Mc_Kinley
M. Celeste Simon
Maria Fardis
Robert A. Mc Cormack
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_cap
|
approximately $1 billion
|
|
gptkbp:partnership
|
gptkb:Novartis
|
|
gptkbp:product
|
Lifileucel
|
|
gptkbp:product_type
|
cell-based therapy
|
|
gptkbp:regulatory_compliance
|
under review
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
tumor-infiltrating lymphocytes
|
|
gptkbp:stock_symbol
|
IOVA
|
|
gptkbp:subsidiary
|
gptkb:none
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.iovance.com
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
4
|